Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host

Caitlin A Trottier; Beverly Wong; Rakhi Kohli; Cassidy Boomsma; Francis Magro; Sucharita Kher; Christina Anderlind; Yoav Golan

doi:10.1093/cid/ciac847

. 2022 Oct 25:ciac847. doi: 10.1093/cid/ciac847

Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host

Caitlin A Trottier ^1,^✉, Beverly Wong ^2,³, Rakhi Kohli ^4,^5,⁶, Cassidy Boomsma ⁷, Francis Magro ⁸, Sucharita Kher ^9,¹⁰, Christina Anderlind ^11,¹², Yoav Golan ^13,^14,¹⁵

PMCID: PMC9620374 PMID: 36281907

Abstract

The management of patients with prolonged viral shedding and COVID-19 symptoms remains unclear. Combining antivirals, as practiced in other infections, is theoretically advantageous. We present a case of persistent, symptomatic SARS-CoV2 infection and associated organizing pneumonia that was successfully treated with an extended course of combination antiviral therapy.

Keywords: SARS-CoV2, COVID-19, Immune compromise

PERMALINK

Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host

Caitlin A Trottier, MD

Beverly Wong, MD

Rakhi Kohli, MD

Cassidy Boomsma, BA

Francis Magro, MD

Sucharita Kher, MD

Christina Anderlind, MD

Yoav Golan, MD

Abstract

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Dual antiviral therapy for persistent COVID-19 and associated organizing pneumonia in an immunocompromised host

Caitlin A Trottier, MD

Beverly Wong, MD

Rakhi Kohli, MD

Cassidy Boomsma, BA

Francis Magro, MD

Sucharita Kher, MD

Christina Anderlind, MD

Yoav Golan, MD

Abstract

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases